was missed medications. The mean time taken to resolve the DKA was 931 (± 574) minutes.

CONCLUSION

Based on the results, the number of readmissions for DKA is worrying and the patients admitted also have high insulin doses, highlighting a possible consequence of over-insulinization. A longer period of evaluation is necessary to investigate the effect of SGLT2 inhibitors use on DKA admissions, as well as further focus on the causes of prolonged time for DKA resolution which may impact the length of hospitalization.

EP_A041

ONE-YEAR TREATMENT OUTCOMES WITH SUBCUTANEOUS SEMAGLUTIDE AT HOSPITAL QUEEN ELIZABETH II: A RETROSPECTIVE ANALYSIS

https://doi.org/10.15605/jafes.039.S1.052

Yee Weai Cheong, Hwee Ching Tee, Jin Hui Ho, Jing Li Lim
Endocrine Unit, Department of Medicine, Hospital Queen Elizabeth II, Kota Kinabalu, Sabah, Malaysia

INTRODUCTION/BACKGROUND

Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) mimic endogenous GLP-1, improving glycemic control and promoting weight loss. Nevertheless, there is limited data available on the effect of semaglutide use among type 2 diabetes (T2D) patients undergoing insulin therapy, particularly those with high insulin requirements.

METHODOLOGY

We aimed to investigate the effects of the addition of subcutaneous semaglutide to a standard regimen of insulin on T2D patients, focusing on changes in HbA1c levels, body weight and total daily dose (TDD) of insulin. In this retrospective chart review, T2D patients who received once-weekly subcutaneous semaglutide with insulin were recruited from the Endocrine Unit of the Hospital Queen Elizabeth II (HQE II) from 2021 to 2023. Follow-up assessments occurred at 3-6 months and 9-12 months post-initiation, with the recording of key parameters such as HbA1c, weight, insulin TDD and adverse events.

RESULTS

Our study recruited a total of 35 patients and found that there were significant improvements across all parameters. HbA1c levels decreased from a mean of 8.9% at baseline to 7.7% at 9-12 months, representing a reduction of 1.2% (p <0.001). Weight decreased from a mean of 92.0 kg at baseline to 84.2 kg at 9-12 months, with a mean reduction of 7.7 kg (-8.4%) (95%CI: 4.9-10.6, p <0.001). Insulin TDD decreased from a median of 72u (40 - 114) at baseline to 48u (24 - 80) at 9-12 months (p <0.001). Six individuals experienced gastrointestinal side effects, with one discontinuing due to intolerable diarrhea. In the subgroup with insulin resistance, there were profound reductions in TDD of insulin used without compromising glycemic control.

CONCLUSION

The study confirmed the efficacy of once-weekly semaglutide in managing T2DM patients on insulin therapy, including those on basal-bolus and pre-mixed regimens. Further research is recommended to assess its effects on patients with high insulin requirements.

EP_A042

RISK OF KETOACIDOSIS WITH LUSEOGLIFLOZIN IN TYPE 2 DIABETES MELLITUS PATIENTS ON MODERATE DOSE INSULIN THERAPY: A RANDOMISED CONTROL TRIAL

https://doi.org/10.15605/jafes.039.S1.053

Aimi Fadilah Mohamad,[1] Nur Aisyah Zainordin,[1] Nur Aini Eddy Warman,[1] Mohd Hazriq Awang,[1] Fatimah Zaherah Mohamed Shah,[1] Rohana Abdul Ghani[1,2]
[1]*Fakulti Perubatan, Universiti Teknologi MARA (UiTM), Sungai Buloh, Malaysia*
[2]*Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), Selangor, Malaysia*

INTRODUCTION/BACKGROUND

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, one of which is Luseogliflozin, are associated with a recognized risk of euglycemic diabetic ketoacidosis (DKA) particularly in patients on insulin therapy.

METHODOLOGY

This study aimed to assess the risk of ketoacidosis with Luseogliflozin in patients with type 2 diabetes mellitus (T2D) on moderate doses of insulin. This study involved patients who were attending the Endocrine Clinic, with stable disease and no recent acute events. The participants were randomized to either add-on Luseogliflozin to standard medical therapy or standard medical therapy only. Ketoacidosis was assessed using fasting blood and urine ketone pre- and post-intervention. The study duration was 12 weeks. Independent t-test was performed to assess changes in ketone levels. Pearson's Correlation was performed to determine the relationship between ketone levels with HbA1c and fasting blood glucose.